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Abstract
Higher body mass index (BMI) measured before endometrial cancer diagnosis has been
associated with greater risk of developing endometrial cancer and higher mortality, but the
association between BMI measured after diagnosis and mortality risk is unclear. We identi-
fied 467 women (91 deaths) in the Women’s Health Initiative (WHI) with information on BMI
measured after diagnosis and used Cox proportional hazards regression to generate hazard
ratios (HR) and 95% confidence intervals (CI) for all-cause mortality. Comparing BMI 35+
with <25 kg/m2, we observed no association with all-cause mortality (HR = 1.02, 95% CI
0.55–1.91). Our study does not support the hypothesis that higher BMI after endometrial
cancer diagnosis is associated with poorer survival.
Background
There is consistent evidence that higher body mass index (BMI) is associated with higher risk
of incident endometrial cancer [1]; each 5-unit BMI increase has been associated with a 59%
increased risk of developing endometrial cancer [2]. Published studies of BMI measured before
endometrial cancer diagnosis and all-cause mortality showed an approximate 2-fold increase
in both all-cause and endometrial cancer specific mortality [3, 4].
While observational studies of BMI measured after diagnosis and mortality among breast
cancer survivors (another BMI-related cancer) have suggested worse survival with higher BMI
[5], evidence on BMI measured after diagnosis and mortality among women diagnosed with
endometrial cancer is limited. An estimated 70% of endometrial cancer survivors are obese
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[6], constituting a potential public health target for weight loss. In the present study we draw
on data from the Women’s Health Initiative (WHI) Clinical Trial and Observational Study to
confirm our recent findings in the US National Institutes of Health (NIH)-AARP cohort [7]
that higher BMI measured after diagnosis was associated with greater mortality risk among
endometrial cancer survivors.
Materials and methods
Eligibility criteria and recruitment methods for WHI have been published [8]. In short, 161,808
women were enrolled in the WHI between October 1993 and December 1998 from 40 US clini-
cal centers. Eligible women were between 50 and 79 years of age, postmenopausal, had an antic-
ipated survival of>3 years and were accessible for follow-up. Of the 161,808 women enrolled
in WHI, 1,549 were diagnosed with invasive endometrial cancer before September 2013. We
define cancer survivors from the moment of diagnosis, in accordance with guidelines from the
Institute of Medicine, the American Society for Clinical Oncology, and other professional socie-
ties and government entities [9]. We excluded women who reported a hysterectomy before
baseline (n = 20) or prior cancer before baseline visit (n = 114). We also excluded those with
stage 4 disease (n = 77) because it is unlikely that BMI would affect prognosis for metastasized
disease. According to study protocol, BMI data was collected at years 3 and 6 post baseline; of
the remaining 1,338 women, 467 women had data on BMI collected after diagnosis. Women
diagnosed after year six were not eligible for this analysis and we used the BMI measure closest
to diagnosis (median 1.4 years) in the present analysis.
All participants provided written informed consent. Institutional review board approval
was obtained from each of the participating study centers and from the Fred Hutchinson Can-
cer Research Center, which currently serves as the IRB of record for the WHI. In the WHI
there were 40 clinical site IRBs, the coordinating center IRB, and ethical review at NIH; partici-
pants completed informed consent forms approved by local institutional review boards. The
funders had no role in study design, data collection and analysis, decision to publish, or prepa-
ration of the manuscript. More information about proposing a paper using WHI data can be
found online at https://www.whi.org/researchers/SitePages/Home.aspx and proposals can be
submitted to p&p@whi.org
We categorized BMI as normal weight, overweight, class 1 obese, and class 2 obese (18.5-
<25 (referent), 25-<30, 30-<35, 35+ kg/m2). The correlation between pre and post-diagnosis
BMI was r = 0.95. In the study population 40 women lost more than three BMI units (kg/m2),
398 women had no change within 3 units, and 29 women gained three or more BMI units. We
used IVEware 2.0 (Ann Arbor, MI, 2002) to impute values for missing variables (<5% missing
for all categories), using 10 iterations and five imputations. We used Cox proportional hazards
models to estimate hazard ratios (HR) and 95% confidence intervals (CI) in SAS version 9.2
(SAS Institute Inc, Cary NC). Proc mianalyze was used to combine results from the five
imputed datasets. The underlying time metric was calculated from post-diagnosis question-
naire to death or end of follow-up (through September, 2013) whichever occurred first. We
evaluated the proportional hazards assumption by modeling interaction terms of the continu-
ous main exposure with follow-up time for each model, and found no violation of the model
assumptions.
We first built a model adjusted only for age. We added tumor grade and stage to models as
they are strongly associated with survival, and then tested the variables that showed significant
differences by BMI category in Table 1 as confounders and eliminated those that did not
change BMI parameter estimates by>10%. Thus, our final model included age at diagnosis,
tumor stage and grade, diabetes and age at menarche. We added self-reported health status in
BMI and endometrial cancer survival
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Table 1. Baseline characteristics of the women diagnosed with endometrial cancer in the Women’s Health Initiative study populations by level of
baseline body mass index (BMI) (kg/m2) (N = 467).
Body Mass Index (BMI) 18.5-<25 25-<30 30-<35 35+ p-value
Deaths/N 28/127 20/138 22/110 21/92 0.334
Age at diagnosis, years (mean, sd) 67.1 0.7 67.1 0.6 66.6 0.6 65.2 0.6 <0.001
N % N % N % N %
Tumor summary stage 0.758
Localized 113 89.0 125 90.6 97 88.2 85 92.4
Regional/Distant 14 11.0 13 9.4 13 11.8 7 7.6
Tumor grade 0.717
Well differentiated 41 32.3 39 28.3 39 35.5 30 32.6
Moderately differentiated 49 38.6 67 48.6 41 37.3 41 44.6
Poorly differentiated 24 18.9 22 15.9 20 18.2 17 18.5
Anaplastic grade 3 12 9.5 8 5.8 7 6.4 3 3.3
Education 0.013
<High school/ high school graduate 25 19.7 27 19.6 34 30.9 20 21.7
Post high school/ some college 32 25.2 36 26.1 37 33.6 37 40.2
College or graduate degree 70 55.1 73 52.9 39 35.5 34 37.0
Race/ethnicity
Non-Hispanic White 114 89.8 130 94.2 104 94.6 76 82.6 <0.001
African American 2 1.6 5 3.6 3 2.7 14 15.2
Other 10 7.9 3 2.2 3 2.7 2 2.2
Self-reported diabetes 0.003
No 124 97.6 134 97.1 102 92.7 80 87.0
Yes 3 2.4 4 2.9 8 7.3 12 13.0
Age at menarche 0.008
12 yrs old 53 41.7 75 54.4 63 57.3 59 64.1
13+ yrs old 74 58.3 63 45.7 47 42.7 33 35.9
Parity <0.001
Nulliparous 20 15.8 25 18.1 7 6.4 21 22.8
1–2 67 52.8 37 26.8 43 39.1 31 33.7
3–4 33 26.0 60 43.5 40 36.4 28 30.4
5+ 7 5.5 14 10.1 20 18.2 12 13.0
Age at menopause <0.001
<50 45 40.2 41 36.3 38 38.8 15 19.5
50-<55 37 33.0 43 38.1 35 35.7 27 35.1
55+ 28 25.0 29 25.7 18 18.4 26 33.8
Oral contraceptive use 0.063
Never 73 57.5 97 70.3 61 55.5 59 64.1
Ever 54 42.5 41 29.7 49 44.6 33 35.9
Hormone use at baseline <0.001
Never 22 17.3 39 28.3 26 23.6 57 62.0
Former 16 12.6 37 26.8 28 25.5 22 23.9
Current 89 70.1 59 42.8 53 48.2 13 14.1
Smoke 0.601
Never 70 55.1 81 58.7 58 52.7 53 57.6
Former 52 40.9 53 38.4 45 40.9 33 35.9
Current 5 3.9 3 2.2 5 4.6 6 6.5
Self-reported health <0.001
(Continued )
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sensitivity analyses to allay concerns that health status is in the causal pathway between BMI
and mortality. Health status is a strong independent predictor of mortality and it is possible
that higher BMI may lead to health complications that increase risk of mortality. Neither add-
ing trial arm (dietary modification, menopausal hormone therapy, observational study) to the
models, nor stratifying by trial arm changed estimates.
Results
With a median 10.2 years of follow-up, we observed 91 all-cause deaths. Women with a BMI
35+ kg/m2 were slightly younger, less educated, more likely to be African American and to
have diabetes. These class 2 obese women also tended to have a younger age at menarche,
older age at menopause, report never menopausal hormone therapy use, and report worse self-
reported health (Table 1).
Before adjusting for co-variables, the log-rank test demonstrated a non-significant p-
value = 0.364. In multivariate models, BMI was not associated with mortality when comparing
BMI 35+ to<25 kg/m2 (HR = 1.02, 95% CI 0.55–1.91) (Table 2). The addition of self-reported
health status to the models also yielded null results (HR = 0.87, 95% CI 0.45–1.69). We did not
observe differences in the association between BMI and mortality when stratifying by the
median 1.4 years from diagnosis to questionnaire (HR<1.4 years = 0.99, 95% CI 0.75–1.31;
Table 1. (Continued)
Body Mass Index (BMI) 18.5-<25 25-<30 30-<35 35+ p-value
Excellent/very good 98 77.2 91 65.9 68 61.8 36 39.1
Good 24 18.9 40 29.0 39 35.5 41 44.6
Fair/Poor 5 3.9 7 5.1 3 2.7 15 16.3
Marital Status 0.181
Married or living as married 78 61.4 84 60.9 80 72.7 62 67.4
Not married 49 38.6 54 39.1 30 27.3 30 32.6
Randomized to HRT Arm 8 6.3 18 13.0 23 20.9 11 12.0 0.010
Randomized to DM Arm 53 41.7 86 62.3 65 59.1 58 63.0 0.002
Observational Study 68 53.5 42 30.4 32 29.1 26 28.3 <0.001
Abbreviations: SD: standard deviation, HRT: Hormone replacement therapy; DM: dietary modification
Column percentages may not total to 100.0 due to missing data.
P-values were calculated using the t-test for continuous variables and the chi-squared test for categorical variables.
doi:10.1371/journal.pone.0171250.t001
Table 2. Hazard ratios and 95% confidence intervals for body mass index (BMI) and mortality risk among endometrial cancer survivors in the WHI
(n = 467).
Deaths/Total N Model 1 HR (95% CI) Model 2 HR (95% CI) Model 3 HR (95% CI)
BMI, kg/m2
18.5-<25 28/127 1.00 1.00 1.00
25-<30 20/138 0.62 (0.35, 1.10) 0.67 (0.37, 1.21) 0.64 (0.36, 1.16)
30-<35 22/110 0.85 (0.48, 1.48) 0.82 (0.46, 1.45) 0.74 (0.41, 1.34)
35+ 21/92 1.22 (0.68, 2.17) 1.02 (0.55, 1.91) 0.87 (0.45, 1.69)
P-trend 0.476 0.919 0.693
Model 1 was adjusted for age at diagnosis only.
Model 2 was additionally adjusted for tumor stage, tumor grade, diabetes and age at menarche.
Model 3 was adjusted for all of the above factors, in addition to health status.
doi:10.1371/journal.pone.0171250.t002
BMI and endometrial cancer survival
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HR1.4 years = 0.99, 95% CI 0.72–1.35). Adding additional demographic factors as described in
Table 1 did not change interpretation of results.
Discussion
Our results do not support an association between BMI measured after diagnosis and mortal-
ity among endometrial cancer survivors. These findings are in contrast with another study of
post-diagnosis BMI and mortality in the NIH-AARP Diet and Health Study, which found an
approximate 2-fold increase in mortality risk comparing women with a BMI 35+ to normal
weight women (<25 kg/m2) [7]. One reason for these discrepant findings may be due to differ-
ences in the timing of BMI measurement between studies, as BMI was measured a median of
1.4 years after diagnosis in WHI and median 4.1 years after diagnosis in NIH-AARP. In this
WHI study we did not observe effect modification by time from diagnosis to BMI measurement.
While the available metrics the WHI and NIH-AARP populations appeared similar, it is possible
that there were differences in participant characteristics that we were unable to account for in
this analysis. Alternatively, our results may simply show that there is no association between
post-diagnosis BMI and mortality. Another study of endometrial cancer patients who partici-
pated in a randomized surgery and adjuvant radiation therapy found that among 380 patients,
morbidly obese patients (BMI40 kg/m2) had a nearly threefold increased risk of death com-
pared to BMI<30 (HR = 2.77; 95% CI 1.21–6.36); this increased mortality risk was not apparent
among patients with a BMI of 30–39.9 [10]. This finding suggests there may be a BMI threshold
beyond which mortality risk is escalated; still, while there was an association with all-cause mor-
tality, there was no association with endometrial cancer recurrence.
A recent meta-analysis among endometrial cancer survivors showed a dose–response curve
between BMI and all-cause mortality, with a 66% increased risk of death comparing women
with a BMI 40+ to<25 kg/m2 [11]. The timing of BMI measurement in relation to diagnosis
varied in this published meta-analysis. In a previous analysis of endometrial cancer survivors
in WHI, pre-diagnosis BMI measured a median of 5.1 years before diagnosis was associated
with an all-cause mortality risk HR = 1.85 (95% CI 1.19–2.88) comparing women with a
BMI 35 kg/m2 to women with BMI< 25 kg/m2 [4]. It is unclear why we found an associa-
tion between pre-diagnosis BMI and mortality in this cohort but not post-diagnosis BMI. In
future studies it could be important to account for intentional versus unintentional weight
loss, or change in weight from pre to post-diagnosis.
In our previous analysis of pre-diagnosis BMI in WHI, the magnitude of association was
stronger for BMI and endometrial-cancer specific mortality (HR = 2.23, 95% CI 1.09–4.54).
This association was previously measured in the Cancer Prevention Study II, where there was
over a six-fold association between pre-diagnosis BMI 40+ and normal BMI women for endo-
metrial cancer-specific mortality [12]. In the present post-diagnosis cohort we were unable to
assess cause-specific mortality because of insufficient cause-specific deaths. We were not able
to assess associations separately for women with a BMI over 40 because of insufficient num-
bers in this category.
Limitations of our study include the lack of data on treatment, which may in turn affect sur-
vival. However, cancer stage (which we included in our adjusted models) has been shown to
be the strongest predictor of prognosis among women with endometrial cancer [13]. We per-
formed a post-hoc power calculation, whereby for BMI, we had 81% power to detect a HR of
2.23 (the HR for pre-diagnosis BMI and mortality in this WHI cohort) comparing the highest
to the lowest BMI category using a type I error of p = 0.05 (Power 3.0, NCI). We also did not
have enough deaths to perform sub-analyses by cause of death. We were unable to adjust for
physical activity as this data was available for only 158 women. Although we had information
BMI and endometrial cancer survival
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on some comorbidities, there may be unmeasured factors confounding the association between
BMI and mortality that we were unable to account for in this analysis. Selection bias may have
influenced results, as the individuals who had later stage disease may have died before follow-
up. Strengths of the study include the geographic diversity of the cohort, the centralized adjudi-
cated outcomes, and the multiple time points of collection on BMI data, which allowed us to
examine BMI recorded after cancer diagnosis.
While obesity has been recognized as a public health threat in the general population [14],
research focused on cancer survivors may present key opportunities for targeted interventions,
as cancer diagnosis has been cited as a “teachable moment” for lifestyle change [15]. Future
research should explore the effects of change in post-diagnosis BMI on cancer outcomes
including quality of life, fatigue, and biomarkers of recurrence in addition to survival.
In summary, the present findings from the WHI do not support the hypothesis that BMI
measured after diagnosis is associated with survival among women with endometrial cancer.
Additional prospective data from larger cohorts with greater variation in timing and frequency
of post diagnosis BMI assessment are needed to further clarify this association that has impor-
tant implications to public health and women’s healthcare in an aging population.
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